StockNews.com Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

Research analysts at StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Other research analysts have also issued reports about the company. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Trading Up 2.2 %

Shares of TENX stock opened at $6.57 on Friday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The firm’s 50 day moving average is $6.44 and its 200-day moving average is $5.34.

Institutional Trading of Tenax Therapeutics

A number of institutional investors have recently bought and sold shares of TENX. Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics in the 3rd quarter valued at $173,000. Vestal Point Capital LP bought a new stake in Tenax Therapeutics in the third quarter valued at about $288,000. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics in the third quarter valued at about $101,000. Geode Capital Management LLC boosted its holdings in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics during the 4th quarter worth about $1,026,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.